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Abstract: The biology of atypical hemolytic uremic syndrome has been shown to involve 
inability to limit activation of the alternative complement pathway, with subsequent damage 
to systemic endothelial beds and the vasculature, resulting in the prototypic findings of a 
thrombotic microangiopathy. Central to this process is the formation of the terminal membrane 
attack complex C5b-9. Recently, application of a monoclonal antibody that specifically binds to 
C5, eculizumab, became available to treat patients with atypical hemolytic uremic syndrome, 
replacing plasma exchange or infusion as primary therapy. This review focuses on the evidence, 
based on published clinical trials, case series, and case reports, on the efficacy and safety of 
this approach.
Keywords: acute kidney injury, ESRD, thrombotic microangiopathy, kidney, alternative 
complement pathway, complement blockade
Introduction
This article is designed to provide a critical appraisal of the efficacy and safety of 
eculizumab in atypical hemolytic uremic syndrome (aHUS) in children and adults. We 
analyze published work based on the level of evidence from controlled trials through 
anecdotal case series and individual case reports. A MEDLINE search was performed 
to identify all relevant articles using the terms “atypical hemolytic uremic syndrome or 
aHUS” and “eculizumab.” We will review why it has become the treatment of choice 
for aHUS, and current limitations in the data.
Clinically, thrombotic microangiopathy (TMA) can occur in a number of diseases. 
However, the most commonly associated diseases are hemolytic uremic syndrome 
(HUS, either shiga-toxin-associated or aHUS), thrombotic thrombocytopenic purpura 
(TTP), and disseminated intravascular coagulation. HUS is characterized by the triad 
of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and moderate 
to severe acute kidney injury, while TTP is defined by the pentad of MAHA, severe 
thrombocytopenia, fever, and, commonly, neurological impairment and milder acute 
kidney injury than in HUS, although such features may occur in HUS as well. Dis-
seminated intravascular coagulation is rather distinct clinically, with the presence of 
an abnormal coagulation profile predominating, and often associated with sepsis.
aHUS is a prototypic TMA, caused by an inability to stop alternative pathway 
(AP) complement activation of the terminal membrane attack complex (MAC, C5b-9), 
thereby leading to damage of endothelial cell beds through the body, as well as the 
inability to block platelet and white blood cell activation in the circulation, which adds 
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further to the microangiopathic process.1 There is a clear 
genetic underpinning documented in nearly two-thirds of 
aHUS cases, relating to an inactivating mutation in proteins 
that downregulate AP activity (factor H, factor I, membrane 
cofactor protein [MCP or CD-46], thrombomodulin), or with 
an activating mutation in C3 or factor B that renders them 
constitutively overactive and not subject to modulation of 
activity, or through the formation of anti-factor H immuno-
globulin G (IgG) antibodies (which commonly are associated 
with gene rearrangements or deletions in complement factor 
H [CFH]-related protein-1 and -3), all of which lead to AP 
generation of the MAC.
Additional cases of aHUS may be seen in a variety of cir-
cumstances that lead to AP complement overactivity coupled 
with the absence of sufficient regulation, including systemic 
lupus erythematosus, scleroderma, malignant hypertension, 
drugs,2–4 and pregnancy, among other conditions. A recent 
study5 of 193 patients that employed a high-throughput 
genetic screening process demonstrated the ability to find 
most mutations and raised the question of novel genetic vari-
ants in the pathogenesis of aHUS as well. The combination 
of a “predisposing factor” (genetic mutations/variants) with a 
“precipitating factor” (infection, drug, systemic disease, and 
others) may overcome the ability to control AP and, therefore, 
leads to the onset of aHUS. In a recent paper, Jodele et al6 
evaluated candidates for bone marrow transplant regarding 
genetic susceptibility to TMA and found that gene variants in 
complement regulators were more common among patients 
with transplant-associated TMA.
Common to aHUS, regardless of the cause, is the activa-
tion of the MAC, which starts with hydrolysis of complement 
factor C5 into C5a and C5b. The humanized monoclonal 
antibody, eculizumab, binds to the complement protein 
C5 with high affinity and inhibits its cleavage to C5a and 
C5b, thereby preventing the subsequent generation of the 
MAC. Eculizumab contains the murine complementarity-
determining regions of the m5G1.1 monoclonal antibody, 
which were grafted onto the human framework light- and 
heavy-chain variable regions. The use of the germ line 
framework acceptor sequences was employed to minimize 
the potential for immunogenicity. The heavy-chain constant 
region of the parent antibody was replaced by components 
of both human IgG
2
 and IgG
4
 and, therefore, lacks the abil-
ity to activate complement and to bind Fc receptors. Such 
modifications should minimize the potential of eculizumab 
to induce pro-inflammatory responses.7,8
Eculizumab was approved in 2011 in the United States9 
and shortly thereafter in Europe.10 Currently, the drug has 
been used worldwide for the treatment of aHUS. A recent 
consensus document11 almost uniformly recommended that, 
once the diagnosis of aHUS is made, eculizumab should be 
started immediately thereafter.
Reliable tools to monitor the response to eculizumab, 
outside of reversal of the clinical features of aHUS, are yet 
to be defined. In patients with paroxysmal nocturnal hemo-
globinuria (PNH), a complement-mediated disease for which 
eculizumab was first approved, there seems to be a correlation 
between activity of 50% hemolytic complement (CH50) assay 
,10% and free eculizumab levels .50 µg/mL with efficacy 
of the drug in reducing hemolysis.12 Although the use of CH50 
is feasible in daily practice, there is no prospective data in 
patients with aHUS to confirm its usefulness, and a standard 
value to correlate with complement blockade is missing. In 
the National Health Service (NHS) Commissioning Policy on 
aHUS in England report,13 monitoring was done by both CH50 
and AP (AP50) hemolytic assay, where complete absence of 
hemolytic activity was used as criteria for adequate comple-
ment blockade. Based on these criteria, only two out of 43 
patients treated needed increased dosing of eculizumab (one 
child and one adult post-transplant). Jodele et al14 reported 
on the use of eculizumab to treat six children with severe 
hematopoietic stem cell transplant-TMA and adjusted the 
dose for a therapeutic level .99 µg/mL with resolution in 
four of six children. In this study, CH50 was used to monitor 
the level of complement blockade (CH50 level #4 comple-
ment activity enzyme units used in this series), and the authors 
found that children needed higher doses or smaller intervals of 
eculizumab infusions compared with the US FDA-approved 
regimen for children with aHUS. Two patients died despite 
dose intensification, but were critically ill.14
To assess the response to eculizumab in a different man-
ner, and using retrospective data, Noris et al15 documented a 
different biomarker of C5 blockade in patients with aHUS, 
using an ex vivo test that employed vascular endothelial 
cells that predicted clinical effectiveness of eculizumab in 
vivo and might guide drug dosing and/or timing. In this 
study, the authors demonstrated that aHUS patients with or 
without identified complement gene mutations or anti-CFH 
antibodies consistently and chronically activate complement 
on endothelium. Using an in vitro system with adenosine 
diphosphate–activated endothelial cell culture, blood samples 
from patients diagnosed clinically with aHUS, with or with-
out overt TMA, induced more C3 and C5b-9 deposition than 
control sera, documenting the higher sensitivity (100%) of 
this ex vivo assay vs elevated plasma soluble (s)C5b-9 levels 
in detecting complement dysregulation in aHUS. In contrast, 
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this did not happen in patients with C3 glomerulopathy in 
which the AP is dysregulated in the fluid phase, reinforcing 
the concept of an endothelial-restricted complement deposi-
tion in aHUS. C5b-9 deposits were prevented by the anti-C5 
antibody eculizumab. More work remains to understand what 
biomarker of disease activity and efficacy of eculizumab ther-
apy might be appropriate. aHUS-associated mutant proteins 
may often effectively regulate complement in the fluid (blood) 
phase, which would explain the normal or near-normal circu-
lating C3 levels in many mutation carriers. Gain-of-function 
mutations of CFB and C3 form a C3 convertase resistant to 
decay by endothelial cell/membrane-bound regulators. Such 
findings provide strong evidence that aHUS is a disease of 
unrestricted endothelial complement activation.
Treatment of aHUS in the  
pre-eculizumab era
Following the landmark paper published by Bell et al in 
1991,16 plasma exchange/plasma infusion (PE/PI) became 
the initial treatment for most patients with aHUS. Initial 
reports17–19 presented variable outcomes of patients with HUS 
in case series or reports in which laboratory assessments 
for differential diagnosis between shigatoxin HUS, aHUS, 
or TTP were not available. More recently, Noris et al,20 in 
an analysis of 273 patients with either sporadic (n=191) or 
familial (n=82) aHUS and treated with PE/PI, found that two-
thirds of adult patients had a bad outcome (dialysis or death) 
in a 3-year follow-up, which varied according to genotype. 
They reported a mortality rate of 8% and 11%, after first 
manifestation and 3 years of follow-up, respectively. Despite 
case reports of “good” outcomes with plasma therapy (three 
and five patients, respectively),21,22 in a recent report from the 
French group (n=214 patients), the mortality rate was higher 
in children than adults (8% vs 2%) after 4 years of follow-
up, with fatal outcomes, despite initial plasma therapy.23,24 
Cataland et al,25 in a retrospective registry analysis of 
19 patients diagnosed with aHUS, found that only six of the 
16 patients treated with PE/PI had a complete hematologic 
and kidney recovery (and in contrast to seven of the nine 
patients treated with eculizumab). Although the genotype–
phenotype correlation data indicate that MCP mutations are 
associated with a better prognosis than CFH mutations, this 
is not always straightforward, since there are patients who 
present severe and life-threatening manifestations with dif-
ferent degrees of response to plasma therapy independently 
of having an identifiable mutation or not.22,26,27
Among the potential risk factors for apheresis-related 
complications in low-weight patients, such as children 
and small adults, are those related to the relatively large 
extracorporeal volume and the difficulties related to ensuring 
adequate vascular access. There is an almost 50% incidence 
of any adverse event including hypotension, symptomatic 
hypocalcemia, allergic reactions, and catheter-related throm-
bosis, and 1% death rate, in patients undergoing plasma-
exchange therapies.28
De et al29 published a review of 28 pediatric cases of 
aHUS with identified mutations who were treated with sup-
portive measures, PE/PI, kidney transplant (±PE/PI), or liver/
combined liver–kidney transplantation in the pre-eculizumab 
era. Overall, 13 of the 28 patients either died or had a relapse, 
and 15 recovered and were well until last follow-up (the lat-
ter included five patients with MCP mutations). Among the 
20 patients with CFH mutations (homozygous or compound 
heterozygotes), ten either died or relapsed and ten recovered. 
Three patients with anti-factor H antibodies had poor out-
comes (one needed dialysis and two had multiple relapses). 
The authors concluded that, despite major progress in the 
understanding of the underlying pathogenetic mechanisms, 
aHUS remains a severe childhood disease with potential 
adverse outcomes, including the development of end-stage 
renal disease (ESRD), disease recurrence after transplanta-
tion, and death.
Analysis of the published data for 
eculizumab in aHUS
Prospective controlled trials of eculizumab in 
patients with aHUS
In 2013, Legendre et al published the results of the first pro-
spective trials of eculizumab in aHUS conducted in Europe 
and North America with patients 12 years of age or older.30 
These trials had followed upon dozens of anecdotal reports 
of the use of eculizumab for the treatment of aHUS, which 
we review later in this article.
Patients were enrolled in two prospective trials according 
to levels of kidney and hematologic abnormalities:
Trial 1 (“progressive TMA”): kidney impairment 
(creatinine $ upper limit of normal [ULN]) and persistent 
thrombocytopenia (,150×109/L) with evidence of hemolysis 
(low haptoglobin, presence of schistocytes, or lactate dehy-
drogenase [LDH] $ ULN) despite four or more sessions of 
plasma therapy (PE/PI).
Trial 2 (“longstanding TMA”): kidney impairment (crea-
tinine $ ULN) with evidence of hemolysis (low haptoglobin, 
presence of schistocytes, or LDH $ ULN) and no platelet 
count decrease .25% during 8 consecutive weeks during 
plasma therapy.
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Among other inclusion criteria were a disintegrin and 
metalloproteinase with a thrombospondin type 1 motif, mem-
ber 13 (ADAMTS13) activity .5%, and shigatoxin negative 
in stools during enrollment screening. Gene mutations or 
anti-factor H antibodies were not a prerequisite.
While end points were different for each trial (Table 130,31), 
common safety issues were assessed. Both groups received 
eculizumab for 26 weeks according to a previously prede-
termined dosing schedule9 and were allowed to continue in 
an extension-phase study, with the 2-year follow-up results 
published recently by Licht et al.31
In the “progressive TMA trial,” the primary end point 
was to hinder “complement-mediated TMA,” defined by a 
composite measure (Table 1). At the beginning of the trial, 
17 patients (one adolescent) were enrolled, and the median 
interval between diagnosis of aHUS and screening was 
9.7 months. Time from onset of the then-prevalent manifesta-
tion of TMA to screening was 0.8 months.31 Except for one 
patient, all received plasma therapy during the week before 
eculizumab was started. All patients had an eGFR (estimated 
glomerular filtration rate) below 60 mL/min/1.73 m2 for 
17 days (median duration), while eleven patients received 
dialysis either before or at first dose of eculizumab, with 
a median (interquartile range) duration of 22 (1–27) days. 
In this study, seven patients had prior kidney transplants. 
No mutations or factor-H antibodies were found in 24% of 
patients. Patients received eculizumab ranging from 2 weeks 
to 90 weeks in duration (median 64 weeks on treatment), and 
15/17 patients completed 26 weeks of treatment.
Complete TMA response (criteria described in Table 1) 
was reached by 65% and 76% of patients at week 26 and 
2 years, respectively. Many additional analyses were per-
formed based on the data in this trial. Half of the patients 
with thrombocytopenia at baseline had a normal platelet 
count after 1 week, which remained normal at week 26 in 
almost 90% of patients. Normalization of platelet count 
and LDH levels occurred in near 90% of patients, and the 
great majority of patients enrolled did not receive PE or PI 
for the entire duration of the study. After eculizumab treat-
ment, kidney function improved progressively with an eGFR 
increase of 32 mL/min/1.73 m2 from baseline to week 26. In 
80% of patients, dialysis was discontinued, and they remained 
dialysis-free through the treatment period (26 weeks).
Among the 15 patients with aHUS who completed 
26 weeks of eculizumab, 13 were enrolled in the exten-
sion phase.31 At the 2-year time point, eleven of 13 patients 
remained on eculizumab (two had withdrawn because of 
decrease in kidney function). Platelet count was normalized 
in nearly 90% at the 1-year and 2-year cutoffs (two patients 
were withdrawn from the study before 26 weeks of treat-
ment because of lack of improvement). Improvements in 
eGFR were maintained after the first year of this trial. eGFR 
increased from 33 mL/min/1.73 m2 to 37 mL/min/1.73 m2 
between week 26 and the 2-year cutoff, with an absolute mean 
(SD) eGFR of 56 (40) mL/min/1.73 m2 at 26 weeks, and 56 
(30) mL/min/1.73 m2 at the 2-year data analysis. Four of the 
five patients (80%) were able to stop dialysis (one before 
the first dose of eculizumab and three at a mean of 1 week 
after the starting on eculizumab). One patient needed to 
start dialysis during the 26-week study period (this patient 
discontinued the study and was not included in the 2-year 
analysis). Another patient started dialysis on study day 444, 
and also discontinued. In summary, two patients were on 
dialysis at the 2-year cutoff.31 There was the same number 
of transplanted patients, and none lost their graft.
In the second controlled trial, comprising “patients with 
longstanding TMA,”30 patients were eligible for study entry 
if they had kidney impairment, stabilization in platelet count 
for at least 8 weeks before the first dose of eculizumab, and 
received plasma therapy at least once every 2 weeks (but 
no more than three times per week). The primary end point 
(Table 1) for this trial was “TMA event-free status” for at 
least 12 weeks in duration. The interval between diagnosis 
and screening was longer (median, 48.3 months) than seen 
Table 1 Criteria for response to eculizumab in prospective 
trials
Inhibition of “complement-mediated 
TMA” (progressive TMA trial)30
TMA event-free status 
(longstanding TMA 
trial)31
Normal platelet count and normal LDH 
level sustained for at least two consecutive 
measurements over a period of at least  
4 weeks
No decrease in platelet 
count of .25%, no plasma 
exchange or infusion use, 
no initiation of dialysis, 
and normalization of 
hematologic values  
(a normal platelet 
count and LDH level, 
sustained for at least two 
consecutive measurements 
over a period of at least  
4 weeks)
Secondary end points included measures 
of renal function, changes in health-related 
quality of life, pharmacokinetics and 
pharmacodynamics, and safety and  
tolerability
Secondary end points 
included measures of 
kidney function, changes 
in health-related quality of 
life, pharmacokinetics and 
pharmacodynamics, and 
safety and tolerability
Abbreviations: LDH, lactate dehydrogenase; TMA, thrombotic microangiopathy.
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in the progressive TMA trial discussed.30 In the longstanding 
TMA trial, 35% of the participants had no identified muta-
tion in AP complement or the presence of anti-factor H 
antibodies. The majority of patients had chronic renal disease 
(eGFR below 60 mL/min/1.73 m2 for a median of 75 months 
before treatment with eculizumab; two patients on dialysis), 
and with the majority of patients being treated with plasma 
therapy for 10 months (median). Time from onset of the 
clinical manifestation of aHUS to screening was 8.6 months 
(median), and all patients received PE/PI before eculizumab. 
The median (range) duration of dialysis during the current 
manifestation was 1.7 (0.32–3) years. Eight patients had a 
prior kidney transplant.31
In this “longstanding TMA” trial, complete TMA 
response (criteria detailed in Table 1) increased from 25% 
at 26 weeks, to 55% at the 2-year cutoff. Treatment with 
eculizumab varied in length from 26 weeks to 74 weeks 
(median 62 weeks). By week 26, 80% of the patients met 
the primary study end point noted above; four patients did 
not achieve the proposed end point because of variations in 
platelet count, although levels were within normal limits. 
All patients stopped plasma therapy, and none started new 
dialysis.
After starting eculizumab, eGFR increased from 6 mL/
min/1.73 m2 to 9 mL/min/1.73 m2 between baseline and 
week 60; the absolute mean (SD) eGFR also increased from 
37 (21) mL/min/1.73 m2 to 40 (18) mL/min/1.73 m2 at the 
2-year time point. Thereafter, initial eGFR improvements 
were maintained during the 2-year eculizumab treatment. 
Two patients required dialysis at baseline: one was on dialysis 
at the 2-year analysis, and the other received hemodialysis 
until renal transplantation (on day 217). During the 2 years 
of the study, one patient started dialysis (days 695–696) 
during admission for an intestinal hemorrhage and died of 
that complication. There were no new kidney transplants or 
graft losses.
Of the 20 patients (five adolescents) who completed the 
initial 26-week study, 19 entered the extension period, with 
eculizumab continued up to 78 weeks. Eighteen patients 
remained on treatment with eculizumab until the data analy-
sis at 2 years.31 The median (range) duration of eculizumab 
exposure in this trial was 0.31 (0.07–0.35) years.
Both in the “Progressing TMA trial” and in the “Long-
standing TMA trial,” earlier initiation of eculizumab 
(time between the current manifestation and enrollment) 
was associated with a greater improvement in the eGFR. 
Eculizumab responses in the primary end points were 
seen in patients regardless of identified genetic mutations 
or CFH autoantibodies, both in the initial and extension 
phases.30,31
In both trials, a significant improvement in health-related 
quality of life (QOL) was seen with eculizumab treatment.30 
Quality of life started improving after 1 week in the first trial 
and 3 weeks in the second trial, and was maintained over the 
2 years of treatment.31
The dosing of eculizumab was designed to achieve a 
minimum blood concentration of 50–100 µg/mL to ensure 
complete complement blockade and to provide sustained low 
levels of free C5 and high levels of C5 cleavage suppression.30 
A biomarker of terminal complement activity remained 
inhibited over 2 years in both studies,31 as measured by a 
modified CH50 assay (method not described).
Open-label, single-group, multicenter, multinational 
clinical trial in adult patients
This clinical trial, performed after those discussed30,31 and 
registered at www.clinicaltrials.gov as NCT01194973,32 was 
conducted in adult patients with aHUS. This was a 26-week, 
open-label, nonrandomized, single-group, multicenter trial 
of eculizumab in patients with aHUS in which patients could 
continue to receive eculizumab in an extension phase. Adult 
patients ($18 years of age) with a diagnosis of aHUS were 
enrolled at 23 centers in North America and Europe. Eligible 
patients had platelet counts ,150×109/L, hemoglobin levels 
# the lower limit of the normal range, LDH levels $1.5 
times above ULN, serum creatinine levels at or above ULN 
at screening, ADAMTS13 activity $5%, and no positive 
shigatoxin-producing Escherichia coli test. An identified 
complement gene mutation, associated polymorphism, or 
factor H autoantibody was not required. Patients were cate-
gorized according to whether they received PE/PI or not 
during the pretreatment period, defined as beginning on the 
start date of the current aHUS manifestation up to the first 
dose of eculizumab.
Forty-one adult patients with aHUS were treated; 38 (93%) 
completed the initial 26-week clinical study period and 
21 (51%) continued treatment of 1 year during the optional 
extension period. Twenty patients (49%) had one or multiple 
identified mutations in complement genes and/or anti-factor H 
antibody. Thirty patients (73%) were enrolled during their first 
identified clinical TMA manifestation. At screening, the mean 
(SD) platelet count was 119.1 (66.1)×109/L, mean haptoglobin 
was 0.6 (0.4) g/L, and mean LDH level was 492.9 (500.9) U/L. 
Thirty-five patients (85%) received PE/PI before eculizumab 
(mean, 9.6 sessions; range, 1–26) during the pretreatment 
period. Twenty-four patients (59%) were receiving dialysis at 
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baseline, and nine (22%) had a history of prior renal transplan-
tation. Thirty-three patients (80%) had chronic kidney disease 
stage 4 or 5 (eGFR ,30 mL/min/1.73 m2).
A prespecified exploratory analysis33 was conducted as 
part of the trial to investigate the effect of terminal comple-
ment blockade on several biological markers associated 
with proximal and terminal complement overstimulation, 
inflammation, damage of endothelial cells, and coagula-
tion markers, in addition to kidney injury, in patients with 
aHUS. Various biomarkers (plasma complement Ba, serum 
soluble tumor necrosis factor receptor-1 [sTNFR1], plasma 
prothrombin fragment 112 [F112], plasma thrombomodulin, 
urinary cystatin C, tissue inhibitor of metalloproteinases-1, 
b2-microglobulin [b2-M], liver fatty acid binding protein 
[L-FABP-1], creatinine, sC5b-9, and C5a) were used in this 
study, from either serum, ethylenediaminetetraacetic acid 
plasma, or urine samples obtained from patients with aHUS at 
baseline, before eculizumab treatment, and at weeks 1–3, 4–6, 
12–17, 26–33, 38–42, and 49–54 during eculizumab treat-
ment. Levels of plasma and serum markers were evaluated 
from healthy volunteers and patients with aHUS at baseline 
and at regular intervals during eculizumab treatment over the 
course of a 1-year period; markers in urine were evaluated 
over the course of 26 weeks of eculizumab treatment.
At baseline, all biomarkers were elevated significantly in 
the majority of patients with aHUS compared to levels mea-
sured in adult healthy volunteers; 69%–83% of patients with 
aHUS also showed significantly elevated levels of candidate 
renal injury biomarkers (ninefold to 48-fold higher than levels 
measured in healthy people). Levels of these biological mark-
ers were increased in patients who presented hematologic 
improvement from screening to the first dose of eculizumab, 
including those patients receiving plasma therapy.33
Eculizumab treatment reduced terminal complement 
activation (C5a and sC5b-9) and selected renal injury mark-
ers (clusterin, cystatin-C, b2-M, and L-FABP-1) to levels 
observed in the healthy volunteers. It also significantly 
reduced inflammation (sTNFR1), coagulation (prothrombin 
F112 and d-dimer), and endothelial damage (thrombo-
modulin) biomarkers compared to pretreatment levels (and 
frequently to levels seen in healthy individuals). Although 
AP activation and endothelial activation markers decreased, 
their mean levels were still elevated compared to healthy 
volunteers. This may reflect persistent complement activation 
in aHUS, even though terminal complement blockade with 
eculizumab was achieved.33 There were no differences in 
biomarker assessment between patients who were or were not 
treated with plasma therapy before enrollment. Unfortunately, 
controls consisting of patients with similar degrees of chronic 
kidney disease but without aHUS were not studied, so the 
meaning of the changes must be interpreted cautiously. At 
present, there is no uniformly agreed-upon biomarker of 
either disease activity or response to eculizumab.
Anecdotal case reports of use of eculizumab in 
patients with aHUS
Tables 234–49 and 322,50–78 present the case reports of adult 
and pediatric patients with aHUS who received eculizumab 
according to the current label-approved schedule. We were 
able to find that 39 adults and 38 children were treated in the 
absence of a clinical trial in the published literature. Overall 
hematologic and kidney responses to eculizumab, as defined 
and judged by the authors of the case reports, were 90% and 
56% for adults, respectively, and 100% both hematologic and 
kidney response in children receiving eculizumab. Where 
applicable, we describe the precipitating factor of ongoing 
TMA, herein termed the “complement-amplifying condi-
tion.” The reports in which eculizumab was used for diseases 
other than aHUS are not mentioned in this review. The reports 
in which eculizumab was used in a non-FDA-approved dosing 
schedule are mentioned in Table 4.
Eculizumab and kidney transplantation
Recent studies have shown that the risk of post-transplant 
recurrence of aHUS is linked to the underlying genetic 
abnormality.79,80 Higher risks are seen in patients with 
mutations in circulating complement proteins and regula-
tors genes, in contrast to patients with mutations in MCP 
(CD-46) who generally, but not always (such as when the 
MCP mutation is combined with another mutation or high-
risk polymorphism), achieve a good kidney transplant out-
come. Recurrence of aHUS is shown to have dismal graft 
survival,80 and led to the recommendation, therefore, in the 
pre-eculizumab era, that isolated renal transplantation was 
contraindicated in aHUS patients. Combined kidney–liver 
transplantation and prophylactic PE have been used to pre-
vent post-transplant recurrences with variable outcomes.81 
More recently, evidence on the benefits of eculizumab in 
the prevention and treatment of aHUS recurrence has been 
demonstrated (Table 4).
Retrospective, multicenter review of 
eculizumab use in renal transplant 
recipients
Zuber et al conducted a retrospective, multicenter study to 
assess eculizumab for the prevention or treatment of post-
transplant manifestations in patients with aHUS.79,82 From the 
22 patients included in the study, 13 patients were enrolled 
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Table 2 Anecdotal case reports using eculizumab in aHUS in adults
Author  
(year)
Population and  
complement-amplifying  
condition
Number of  
patients  
treated with  
eculizumab
Outcome with eculizumab
Sevinc et al  
(2015)46
woman aged 32 years with plasma-resistant aHUS  
and infection
1 Hematologic recovery; stopped dialysis  
after 3 months
Thajudeen et al  
(2013)47
Man aged 51 years with eculizumab first-line treatment  
and trauma
1 Hematologic recovery; stopped dialysis  
after 2.5 months
Sengul Samanci et al  
(2015)45
Man aged 51 years with plasma-resistant aHUS and  
severe hypertension
1 Hematologic recovery; remained dialysis  
dependent
Rafiq et al  
(2015)42
woman aged 59 years with recurrent TMA and  
accelerated hypertension/illicit drug use
1 Noncompliant and lost to follow-up
Nguyen et al  
(2014)39
Man aged 62 years with CKD3, DM2, and biopsy with  
IgA vasculitis relapse of TMA despite 14 days of PE  
and 1 month of rituximab
1 Hematologic recovery; remained dialysis  
dependent
Rigothier et al  
(2015)43
Adult with distal angiopathy and ESRD 1 Remission of distal angiopathy;  
hematologic recovery; successful kidney  
transplantation
Ohanian et al  
(2011)40
woman aged 50 years with ischemic colitis and  
neurologic impairment
1 Renal and neurologic improvement after  
third dose; hematologic improvement  
after sixth dose
Salem et al  
(2013)44
woman aged 66 years with shigatoxin-negative  
bloody diarrhea, seizures, and coma
1 Stopped dialysis after third dose;  
neurologic recovery at week 7
Povey et al  
(2014)41
woman aged 21 years with neurologic  
involvement (PRES) and past history of TMA
1 Neurologic and hematologic recovery;  
stopped dialysis after 3.5 months
David et al  
(2013)36
woman aged 23 years with SRD and TMA unresponsive  
to PE and steroids and third trimester of pregnancy
1 Hematologic and kidney recovery;  
complete resolution of SRD, and eyes  
remained stable at 2-month follow-up
Ardissino et al  
(2013)34 
Mussoni et al  
(2014)38
woman aged 26 years with relapse of TMA after  
39 sessions of PE during pregnancy and strong family  
history of aHUS
1 Eculizumab infused at 26th week of  
pregnancy with hematologic and  
kidney recovery; patient delivered  
a healthy baby girl at 38th week with  
no signs of TMA
Zschiedrich et al  
(2013)49
woman aged 31 years with plasma-resistant  
postpartum aHUS
1 Eculizumab started at day 18 after  
diagnosis with full clinical resolution and  
creatinine 1.0 mg/dL
Tsai and Kuo  
(2014)48
aHUS was defined by MAHA, thrombocytopenia,  
and renal failure with plasma ADAMTS13 activity  
.10%. Other causes of the syndrome of MAHA and  
thrombocytopenia, such as DIC, systemic autoimmune  
disorders, lupus anticoagulants, metastatic neoplasms, 
shigatoxin, or neuraminidase-associated HUS, were  
excluded 
Case 1: patient presented with bloody diarrhea negative  
for shigatoxins 
Case 2: patient presented 3 months after undergoing  
autologous HSCT for advanced multiple myeloma 
Case 3: patient had recurrent episodes of severe  
hypertension accompanied by mild renal insufficiency  
and MAHA for 4.5 years before he was found to have  
aHUS 
Case 4: patient presented at 22 weeks of her third  
pregnancy and was initially assumed to have preeclampsia;  
however, her disease persisted after termination of  
pregnancy 
Case 5: patient had kidney biopsy performed for renal  
failure at 3 weeks after her seventh triweekly course  
of chemotherapy with gemcitabine and carboplatin for  
metastatic cholangiocarcinoma
5 After eculizumab infusion, platelet count  
began to exhibit steady increase within  
3 days in each of the 5 courses in cases 1–4
No increase in platelet count occurred in  
case 5 while she was being treated with  
eculizumab
LDH normalized by day 14 in cases 3 and 4  
and by day 70 in case 2; it did not normalize 
by day 21 in case 1 and by day 84 in case 5
Improvement of renal function by 1 stage  
was observed: 
By day 14 in case 4 
By day 63 in case 3 
By day 378 in case 2 (with further  
improvement by 1 stage by day 483)
(Continued)
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in Europe82 and nine were reviewed from the published 
literature.83–85 Cases were reported in two groups: 1) patients 
who received eculizumab prior to transplantation to prevent 
subsequent TMA manifestations (n=9); and 2) patients who 
received eculizumab to treat post-transplant aHUS mani-
festations (n=13). Individual patient information describing 
eculizumab use prior to the transplantation is included in 
Table 4.52,53,73,79,82,86–98
Use of eculizumab prior to transplantation (n=9)
Nine patients received eculizumab prior to transplantation to 
prevent post-transplant aHUS manifestations and allograft 
loss. Five patients had heterozygous mutations in CFH, three 
had a large CFH/CFHR1 nonhomologous recombination, and 
one had a gain-of-function C3 mutation. Three patients had 
received four kidney transplants, all lost to post-transplant 
aHUS manifestations. Median age at time of present trans-
plant was 9 years (range, 6.4–41.0 years). Two patients had 
preformed donor-specific antibodies with low titer (mean 
fluorescence intensity ,1,000) at the time of transplantation. 
Strategy around the use of eculizumab consisted of one of the 
following three methods: 1) PE started just before transplanta-
tion, then switched to eculizumab after transplantation (n=2); 
2) eculizumab initiated 1 week or more before transplantation 
(n=2); and 3) eculizumab initiated #24 hours before trans-
plantation with additional dose immediately before (n=1) 
or within 24 hours after (n=4) transplantation. Eight of nine 
patients treated with eculizumab maintained allograft function 
and experienced no additional post-transplant aHUS manifes-
tations from 2–39 months of follow-up (mean 14.5 months). 
One allograft (case #8, Zuber et al82) was lost to immediate 
arterial thrombosis, despite undetectable CH50 activity. This 
patient was ultimately successfully retransplanted under peri-
transplant eculizumab therapy.11 No significant infectious 
complications were reported.
Post-transplant treatment of aHUS with eculizumab 
(n=13)
From the 13 patients who received eculizumab to treat post-
transplant aHUS, two received it because of intolerance to 
plasma therapy or convenience. Ten patients presented with 
plasma-resistant aHUS. One was treated with complement 
Table 2 (Continued)
Author  
(year)
Population and  
complement-amplifying  
condition
Number of  
patients  
treated with  
eculizumab
Outcome with eculizumab
Fakhouri et al  
(2014)37
19 patients who had received four or more weekly  
900 mg infusions of eculizumab were identified through  
a query sent to all nephrology centers in France
aHUS was defined as three or more of the following:  
acute kidney injury (serum creatinine .1.4 mg/dL  
[120 µmol/L]), mechanical hemolytic anemia, 
thrombocytopenia, and the presence of TMA features  
in a kidney biopsy specimen
For first-line therapy, 16 patients underwent plasma 
exchange and 3 patients received eculizumab
19 Median time between aHUS onset and 
eculizumab therapy initiation was 6 days 
(range, 1–60 days), and median time to 
platelet count normalization after  
eculizumab therapy initiation was 6 days 
(range, 2–42 days). At the 3-month  
follow-up, 4 patients still required dialysis,  
8 had non-dialysis-dependent CKD, and 
7 had normalized kidney function. At last 
follow-up (range, 4–22 months),  
3 patients remained dialysis dependent,  
7 had nondialysis-dependent CKD 
(estimated glomerular filtration rate,  
17–55 mL/min/1.73 m2), and 9 had normal 
kidney function. Risks of reaching end-stage 
renal disease within 3 months and 1 year 
of aHUS onset were reduced by half in 
eculizumab-treated patients compared with 
recent historical controls
Ardissino et al  
(2014)35
Three cases of patients with aHUS and CKD  
(case 3 post-kidney transplant) who developed skin  
lesions that completely recovered when disease-specific  
treatment was established
One patient responded to plasma therapy, and 2 also  
received eculizumab
2 Complete recovery of active skin lesions 
and hematologic parameters after 
eculizumab treatment
Abbreviations: ADAMTS13, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13; aHUS, atypical hemolytic uremic syndrome; CKD, 
chronic kidney disease; CKD3, chronic kidney disease stage 3; DIC, disseminated intravascular coagulation; DM2, type 2 diabetes mellitus; ESRD, end-stage renal disease; 
HSCT, hematopoietic stem cell therapy; HUS, hemolytic uremic syndrome; IgA, immunoglobulin A; LDH, lactate dehydrogenase; MAHA, microangiopathic hemolytic anemia; 
PE, plasma exchange; PRES, posterior reversible encephalopathy syndrome; SRD, serous retinal detachment; TMA, thrombotic microangiopathy.
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Table 3 Anecdotal case reports of use of eculizumab in children and adolescents with aHUS
Author  
(year)
Case presentation and  
complement-amplifying condition
Number of  
patients  
treated with  
eculizumab
Outcome with eculizumab
Diamante Chiodini et al  
(2014)60
Boy aged 8 years with shigatoxin-negative bloody  
diarrhea and severe neurologic impairment  
resistant to plasma therapy
1 Eculizumab started on day 37 with complete recovery 
of neurologic and hematologic parameters and 
improvement in kidney function (stopped dialysis 
after first dose)
Coppo et al  
(2015)58
Girl aged 4 years with lupus nephritis resistant  
to conventional therapy and features of aHUS
1 Prompt remission of vasculitis, proteinuria, and 
hematuria; normalization of renal function; 2 attempts 
to withdraw eculizumab followed by severe relapses 
and rescued by reinstating treatment; received 
eculizumab treatment for .17 months without 
relevant side effects.
vaisbich et al  
(2013)77
Boy aged 14 months with aHUS, hypertension,  
and proteinuria
1 Hematologic improvement; stopped dialysis after 
second dose of eculizumab
Hisano et al  
(2015)65
Boy aged 4 years with aHUS, nonoliguric  
kidney injury, macrohematuria, and anti-factor H  
antibodies
1 Macrohematuria disappeared after second dose; 
discharged with complete hematologic and kidney 
resolution
Noone et al  
(2012)71
Boy aged 13 years with post-kidney transplant  
TMA, AMR, and aHUS
1 Kidney function recovery with AMR treatment and 
eculizumab; graft lost due to BK (polyomavirus) 
nephropathy
Cullinan et al  
(2015)59
Girl aged 8 months with aHUS and multiple  
TMA relapses treated with 212 sessions of PE;  
mother has aHUS
1 Patient treated with eculizumab for 52 months with 
complete remission and no relapses
Mache et al  
(2009)68
Boy aged 17.8 years with plasma-resistant  
aHUS
1 Hematologic recovery and partial kidney function 
improvement; eculizumab used only on relapses and 
progressed to ESRD
Belingheri et al  
(2014)54
Young male, first presentation at 6 months,  
remained with CKD until age 7 years, when PI  
was started because of relapses; remained with  
CKD, proteinuria, and hypertension
1 Eculizumab started at age 11 years with no more 
relapses; decrease in proteinuria, and no need for 
dialysis
Christmann et al  
(2014)57
Girl aged 5.5 months with aHUS and severe  
hypertension
1 Hematologic improvement on day 3; stopped dialysis 
2 weeks after first dose
Dorresteijn et al  
(2012)61
Girl aged 6 years with aHUS treated initially  
with PE for 3 weeks, followed by PI; developed  
relapse during upper respiratory infection,  
and PE did not improve renal function despite  
platelet count normalization
1 Renal function started to improve 48 hours after first 
eculizumab dose; complete remission achieved until 
last follow-up 9 months later
Bekassy et al  
(2013)53
Girl aged 12 years with aHUS and kidney failure  
since age 20 months; bilateral nephrectomy and  
a lost graft due to aHUS; at 10 years of age,  
transient ischemic attack and occlusion of  
carotid arteries
1 Started eculizumab without overt TMA and despite 
being anephric. She received a successful kidney 
transplant and did not have progression of carotid 
lesions
Hu et al  
(2014)66
19-month-old girl with severe neurologic  
involvement and cardiomyopathy
1 Eculizumab infused 12 hours after admission. Normal 
echocardiography on day 15, stopped dialysis on day 
18, and was discharged with mild hemiparesis, but 
completely alert
Tschumi et al  
(2011)76
Girl aged 9 years with plasma-dependent  
aHUS
1 Eculizumab started on day 126; PE was stopped and 
there were no relapses in 24 months of follow-up. 
Mild CKD due to fibrosis
Michaux et al  
(2014)70
Neonate aged 11 days with severe aHUS  
(myocardial impairment, respiratory failure,  
acute kidney disease requiring hemodiafiltration)
1 Early treatment with eculizumab as first-line therapy 
and completely recovered within 5 days. with .24 
months of follow-up, renal function remains normal
Ohta et al  
(2015)72
Boy aged 4 months who developed aHUS;  
repeated plasma infusions and 9 sessions of  
plasmapheresis were ineffective. The patient  
initially required continuous hemodiafiltration  
and thereafter peritoneal dialysis
1 Eculizumab started on day 48 of diagnosis with 
improvement in hypertension, and dialysis was 
stopped on day 117. CKD2 at 17 months of follow-up
(Continued)
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Table 3 (Continued)
Author  
(year)
Case presentation and  
complement-amplifying condition
Number of  
patients  
treated with  
eculizumab
Outcome with eculizumab
Ariceta et al  
(2012)51
Boy aged 28 days with plasma-resistant aHUS.  
He developed multiple intestinal perforations  
and leg skin necrosis due to systemic TMA
1 Within 48 hours of first eculizumab infusion, the 
patient recovered from acute kidney failure, with 
complete hematologic remission 2 weeks later
Al-Akash et al  
(2011)50
Boy aged 15 years with aHUS since age  
16 months, ESRD and two failed kidney  
transplants
1 Eculizumab used as rescue of aHUS after the third 
kidney transplant with complete recovery of renal 
function 3 weeks after the first dose
Roman-Ortiz et al  
(2014)73
Boy aged 9 years presented with aHUS at age 3;  
irreversible renal failure and uncontrolled severe  
hypertension with concentric left ventricular  
hypertrophy, recurrent acute pulmonary edema,  
and congestive heart failure despite 5 hypotensive  
agents and bilateral nephrectomy
1 Kidney transplant performed with prophylactic 
eculizumab; after 3 years of continuous use, 
hypertension is controlled, no left ventricular 
hypertrophy, no opportunistic infections, and negative 
clinical chemistry parameters for hemolysis
Cayci et al  
(2012)56
Girl aged 10 years with negative-culture bloody  
diarrhea and plasma-resistant aHUS
1 Eculizumab started on day 15 with diuresis 
improvement in 24 hours and complete hematologic 
and kidney recovery in 2 weeks
Lapeyraque et al  
(2011)67
Girl aged 7 years with aHUS. weekly PI with  
short-term intensified PI during aHUS  
exacerbations was effective for 4.3 years;  
progressive mild renal failure (stage 2) and aHUS  
exacerbation unresponsive to intensified PI
1 Eculizumab was started with complete reversal of 
TMA after 1 week; no relapses and normal kidney 
function after 12 months of follow-up
vilalta et al  
(2012)78
Girl aged 4 years with multiple severe clinical  
manifestations including acute kidney injury,  
dilated cardiomyopathy, and cardiorespiratory  
arrest; intense PE did not halt TMA  
manifestations
1 The initial single dose of eculizumab only temporarily 
improved the clinical symptoms of TMA; sustained 
improvement of renal, hematologic, and cardiac 
values were achieved only upon institution of chronic 
treatment with eculizumab (2.5 years)
Azukaitis et al  
(2014)52
Boy with first manifestation of aHUS at age  
2 months and a relapse at age 10 months leading  
to ESRD despite PI. Remained hypertensive  
in dialysis and had convulsions at age 5.5 years,  
when stenosis of left carotid artery and bilateral  
middle cerebral arteries was diagnosed
1 At age 6.5 years received a kidney transplant under 
prophylactic eculizumab with no signs of post-
transplant aHUS; evolved with seizures and cerebral 
ischemia on the fourth postoperative day, leading to 
death
Sharma et al  
(2015)75
Girl aged 28 days presented with plasma-resistant  
aHUS with gross hematuria and hypertension
1 After 1 dose of eculizumab, dialysis was discontinued 
and her hematologic parameters improved; after 
11 months of follow-up, she remains on eculizumab 
and penicillin without recurrence of aHUS or any 
infectious complications
Besbas et al  
(2013)55
Newborn aged 5 days with aHUS and full renal  
and hematologic remission after PI. The patient  
was discharged with FFP infusions but  
subsequently developed 3 life-threatening  
disease recurrences at 1 month, 3 months, and  
6 months of age. The last relapse presented with  
uncontrolled hypertension and impaired renal  
function while the patient was receiving FFP  
infusions
1 Five days following the first dose of eculizumab, renal 
and hematologic parameters returned to normal 
range and blood pressure normalized; FFP infusions 
were gradually decreased and stopped; at the time 
of the report, the patient was 20 months of age 
and currently on eculizumab treatment every other 
week with completely normal renal and hematologic 
parameters
Giordano et al  
(2012)62
Boy aged 8 months with aHUS resistant to  
21 PI and 15 PE treatments
1 Eculizumab first dose at age 12 months with 
hematologic improvement in 1 week and dialysis 
cessation in 5 days; no relapses and no PE/PI needed
Schalk et al  
(2015)74
Boy aged 3 years with aHUS and frequent  
relapses requiring PI
1 Started eculizumab and continued presenting relapses 
despite complement blockade; the authors decided 
to administer the medication immediately in times 
of immunologic triggers, such as immunizations or 
infections; at the time of report, the patient had been in 
a stable condition with an eGFR of 90 mL/min/1.73 m2 
and no further TMA events for more than a year
(Continued)
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Table 3 (Continued)
Author  
(year)
Case presentation and  
complement-amplifying condition
Number of  
patients  
treated with  
eculizumab
Outcome with eculizumab
Gulleroglu et al  
(2013)64
Girl aged 11 years developed aHUS and was  
treated immediately with PE/PI. Although initial  
improvement in renal function was seen, patient  
showed progressing TMA despite daily PE,  
and neurologic manifestations developed after  
1 month 
Girl aged 6 years developed cerebral  
TMA (seizures, vision loss, and nystagmus) 6 days  
after initial presentation and remained  
unresponsive to PE/PI
2 Treatment with eculizumab achieved complete 
control of neurologic symptoms within 24 hours 
and gradually normalized hematologic and renal 
parameters in both children
Malina et al  
(2013)69
Girl aged 4 years developed gangrene of the  
fingertips 2 days after initial presentation of aHUS. 
Renal function continued to decline despite daily  
PE, and she was started on peritoneal dialysis  
5 days after admission. The distal tips of the  
left hand remained gangrenous with a line of 
demarcation. Three weeks later, she did not  
return for follow-up and died at home because  
of dialysis-related complications
Another girl developed ESRD due to aHUS in  
the fourth month after birth. At age 9 months,  
she suddenly developed ischemic changes in  
fingers of both hands and several toes. The  
lesions progressed, and several fingertips  
became gangrenous despite intense PE therapy
1  
 
 
 
 
 
 
 
 
Eculizumab was started on the second case and all 
non-necrotic digits rapidly regained perfusion. The 
3 already gangrenous fingers healed with loss of the 
end phalanges; during maintenance, eculizumab aHUS 
activity subsided completely, and some late recovery 
of renal function was observed
Baskin et al  
(2015)22
Retrospective analysis of 15 children diagnosed  
with aHUS, which was defined as HUS negative  
for STEC
Three patients had relapses, and 7 had a new 
diagnosis. Nine children had oliguria or anuria,  
and 8 required dialysis. Hypertension was  
observed in 6 patients. Neurologic involvement  
developed in 6 patients.
10 Ten were resistant to, or dependent on, plasma 
therapy and treated with eculizumab; following the 
start of eculizumab treatment, all patients achieved 
full recovery of renal function and hematologic 
parameters.
Gruppo and Rother 
(2009)63
Congenital aHUS: first manifestation at 8 days  
of life treated with PI; relapses at 3 months,  
9 months, and 11 months of age; all treated with  
PI with good response after 2 weeks; fourth  
relapse at 18 months unresponsive to PE.
1 Eculizumab was initiated at day 35 of the fourth 
relapse with improvement in hemolysis in 48 hours 
and complete remission in 10 days (with no PE/PI)
Abbreviations: aHUS, atypical hemolytic uremic syndrome; AMR, antibody-mediated rejection; CKD, chronic kidney disease; CKD2, chronic kidney disease stage 2; eGFR, 
estimated glomerular filtration rate; ESRD, end-stage renal disease; FFP, fresh frozen plasma; PE, plasma exchange; PI, plasma infusion; STEC, shigatoxin-producing Escherichia 
coli; TMA, thrombotic microangiopathy.
blockade as first-line treatment. No mutations were found 
in two of the 12 patients screened. Overall, there were 
17 renal transplants, and 14 had been lost by aHUS recur-
rence, two by vascular thrombosis, and one by chronic 
allograft nephropathy. The median interval between renal 
transplantation and recurrence was 2 months (from 3 days 
to 5 years). The delay between recurrence and treatment with 
eculizumab was 30 days (from 1 day to 14 months).
Donor-specific antibodies were not detected in any 
patient, and histological findings of TMA were present on 
biopsy in 77% of patients (of which one only exhibited 
signs of antibody-mediated rejection). All but three patients 
were maintained on eculizumab until last follow-up. Two 
patients who received a single dose of eculizumab presented 
a relapse after aHUS remission, but this did not resolve 
with eculizumab reintroduction; the patients progressed to 
ESRD. In all patients, there was good hematologic response 
(defined by the authors), as well as kidney function improve-
ment. In the patients unresponsive to plasma therapy, renal 
function recovery was inversely proportional to the delay 
in starting eculizumab therapy, as few patients had kidney 
function benefit when the drug was started after 1 month. 
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Two patients presented with a pulmonary infection by M. 
tuberculosis and H. influenza, respectively, and one patient 
had hypogammaglobulinemia (history of prior splenectomy 
and use of rituximab), but good outcome with antibiotics and 
subcutaneous immunoglobulin.
Retrospective single center case 
series of eculizumab use in renal 
transplant recipients
Matar et al90 reported a retrospective study of 12 consecu-
tive patients with an established diagnosis of aHUS who 
underwent at least one kidney transplant at a single institu-
tion between 2003 and 2013. Diagnosis of primary aHUS 
was confirmed by evidence of thrombocytopenia, hemolytic 
anemia, acute renal failure, normal ADAMTS13 levels, and 
negative for shigatoxin-producing E. coli-HUS.
Six patients had an established diagnosis of aHUS as their 
primary disease prior to their first transplant, three patients 
were diagnosed with aHUS post-transplant, two patients had 
an unclear diagnosis as the cause of the primary disease, and 
one patient was diagnosed with focal segmental glomerular 
sclerosis as their primary disease. All patients had genetic 
testing for complement mutations: six patients (50%) had 
identified complement mutations, including four with CFH 
mutations, one with an MCP mutation, and one with a THBD 
mutation. The 12 patients received a total of 23 kidney 
transplants. Six patients had only a single transplant, three 
patients had two transplants each, and three patients had more 
than two transplants. Four patients considered at high risk 
of post-transplant TMA complications received eculizumab 
starting 24 hours prior to transplantation. Individual patient 
information is included in Table 5. All patients maintained 
allograft function, and there were no reported TMA compli-
cations with 21–34 months of follow-up.
Retrospective, multicenter review 
of eculizumab use for aHUS in 
England
Sheerin et al13 reported on the use of eculizumab com-
missioned by NHS England in 2013 for both new patients 
with aHUS and long-duration aHUS, including those who 
underwent renal transplantation. Overall, 43 patients received 
eculizumab: 15 (35%) were ,18 years (eleven male, four 
female); 28 (65%) were adults (nine male, 19 female); 23 
(53%) had active progressing TMA, and 20 (47%) had a 
long duration of aHUS. At the time of publication, 31 (72%) 
patients were receiving ongoing eculizumab. Three of 14 
(21%) patients who discontinued eculizumab had subsequent 
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TMA complications and recommenced therapy with eculi-
zumab (including two patients on dialysis who did not recover 
renal function but had ongoing hemolysis).
At the moment of publication, there were 45 patients (43 
adults/two children) on dialysis in England whose primary 
diagnosis was aHUS. Mutations were identified in 32 (71%) 
of patients. Of the 13 patients without an identified muta-
tion, five (38%) had lost a previous transplant to recurrent 
disease. This suggests that in these individuals there is an 
as-yet unidentified inherited or acquired factor that caused 
recurrent disease. The majority had not been wait-listed due 
to risk of subsequent TMA manifestations, and wait listing 
was made possible with the introduction of the NHS England 
Commissioning Policy for aHUS.
Use of eculizumab prior to renal transplantation
In the report by Sheerin et al,13 from April 1, 2013, to March 
31, 2014, nine of 45 (20%) aHUS patients received a renal 
transplant with eight (89%) receiving eculizumab prior to 
transplantation. One patient received eculizumab for subse-
quent TMA in the early postoperative period, and all of these 
renal transplant recipients had good transplant outcomes and 
continue to receive eculizumab.
Treatment of prevalent patients not on dialysis
Of the eleven patients with long-duration aHUS who were 
not on dialysis, eight received eculizumab to prevent further 
relapses. One of these was a patient with a known CD46 
mutation who had recurrent episodes of pancreatitis that did 
not respond to eculizumab, which was withdrawn. Three were 
transplant patients—one started eculizumab 29 months after 
transplant when a biopsy undertaken for progressive decline 
in transplant function showed evidence of a chronic TMA 
with graft function improvement after eculizumab; two other 
transplant patients (deemed to have typical HUS) developed 
a TMA in the graft early after transplantation leading to a 
revised primary renal diagnosis of aHUS, both of whom had 
good outcome with eculizumab treatment.
Case reports of kidney transplant 
patients with aHUS treated with 
eculizumab
Cases describing use of eculizumab in patients with aHUS 
prior to transplant and long-term use after kidney transplanta-
tion to prevent TMA and therefore the risk of allograft loss 
are summarized in Table 5.11,40,82,83,90,97,99–108 Of the 26 cases 
backed with adequate follow-up information, 24 patients 
(92%) remained free of TMA complications with stable graft 
function at last follow-up (range, 3 days to 39 months). We 
refer you to the full publications for complete details.
Limited patient-level information was available in the 
case series presented by Sheerin et al;13 therefore, these are 
not presented in Table 5.
Safety
Terminal complement activity (MAC) is required for pro-
tection from invasive meningococcal disease, and use of 
eculizumab would heighten the exposure of patients to this 
risk. Immunization is required by regulatory authorities 
for the use of eculizumab, and antimicrobial prophylaxis 
is suggested in the early days after such immunization (on 
label). In the prospective trials,30 meningococcal infection, 
infection-related serious adverse events, and deaths were 
not reported, and this continued throughout the extension 
study.31 In trial 1 (“progressive TMA”), serious adverse events 
were reported in all patients, one of which was considered 
severe (hypertension in a chronically hypertensive patient). 
In trial 2 (“longstanding TMA”), half of the patients had 
serious adverse events. All serious adverse events related to 
eculizumab had resolution without interruption of the drug. 
Beyond the 26th week of treatment, no new adverse events 
were reported and were similar among different subgroups, 
including transplant recipients. It is noteworthy that adverse 
events were reported to diminish over time from week 26 to 
the 2-year cutoff, and no new or cumulative adverse events 
were noted.31
In the series published by Sheerin et al13 regarding 
the NHS England Commissioning Policy for aHUS, there 
were no meningococcal infections described in 43 patients 
treated with eculizumab and vaccinated according to local 
guidelines.
The presence of non-neutralizing human anti-human anti-
bodies was confirmed in one patient in trial 1 who received 
a single dose of eculizumab and discontinued following 
diagnosis of systemic lupus erythematosus (an exclusion 
criterion).
In a 10-year-old boy with aHUS and heterozygous factor 
H mutation who received eculizumab to avoid recurrence of 
aHUS in the renal allograft, protective serum bactericidal 
antibody titers ($1:8) were seen after kidney transplanta-
tion under immunosuppressive therapy with mycopheno-
late mofetil, tacrolimus, steroids, and eculizumab over a 
27-month observational period. This case illustrates that a 
humoral immune response to conjugate meningococcus C 
vaccination may occur and be maintained despite chronic 
renal disease, kidney transplantation, immunosuppressive 
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drugs, and immunomodulatory therapy with eculizumab. 
However, it remains unclear whether serologically defined 
protective serum bactericidal antibody titers mediate true 
protection from invasive meningococcal disease in an immu-
nocompromised patient, particularly if undergoing treatment 
with a complement inhibitor.109
A 24-year-old man with diarrhea found to have acute 
renal failure with MAHA was diagnosed with aHUS. He was 
initiated on PE and hemodialysis. On day 6, he was started 
on eculizumab. His renal function progressively improved. 
His main complication during eculizumab therapy was 
hypertension-related posterior reversible encephalopathy 
syndrome.110
The complement system plays a vital role in pre-
venting life-threatening infections by ensuring optimal 
functioning of the host immune system. Its dysregulation 
has been implicated in causing glomerular, hematologic, 
and transplant-related disorders. Vellanki and Bargman111 
describe a very rare case of Aspergillus niger peritonitis 
in an ESRD patient on peritoneal dialysis receiving main-
tenance eculizumab therapy for aHUS. Given that murine 
models with the same defect as that induced by eculizumab 
are vulnerable to invasive aspergillosis, it is suggested that 
the fungal peritonitis in this patient was the result of the 
eculizumab therapy.111
The long-term safety and efficacy of eculizumab in the 
pediatric population remain under review. Cullinan et al59 
presented the case of a child with a hybrid CFH/CFHR3 
gene who, having had multiple disease relapses despite 
optimal treatment with PE, commenced eculizumab therapy 
in August 2010. She remained relapse-free in follow-up at 
52 months, and treatment has been well tolerated. Despite 
vaccination against meningococcal disease and appropriate 
antibiotic prophylaxis, the patient developed meningococcal 
bacteremia 30 months into treatment. She presented with 
nonspecific symptoms but recovered without sequelae with 
appropriate treatment. The authors suggest vaccination, 
antibiotic prophylaxis, and annual monitoring and follow-up 
of vaccine responses.59
A recently published case series in a pediatric popula-
tion112 described a possible relationship of liver injury with 
the use of eculizumab in eleven children treated with this 
drug for aHUS in a single center. Elevated liver enzymes were 
reported in seven children (ages 6–11 years) after starting 
eculizumab infusions to treat aHUS. Liver enzyme thresholds 
for drug-induced liver injury (international patterns) were 
exceeded in five cases, all of which were classified as mixed 
hepatocellular/cholestatic. Other causes for liver injury such 
as infections were excluded. One patient developed tender 
hepatomegaly and a 20-fold liver enzyme elevation after start-
ing eculizumab. Recurrent liver injury following resumption 
of treatment with eculizumab led to its discontinuation and 
conversion to plasma therapy. Thus, hepatotoxicity in patients 
treated with eculizumab for aHUS should be monitored. 
Despite this clinical finding, further research is necessary to 
characterize the mechanism of potential hepatotoxicity and 
also to identify patients at risk.112
Eculizumab has been used in pregnant women success-
fully, albeit with PNH113 and not aHUS. Recently, a case 
report of safe use of eculizumab in a 26-week pregnant 
woman with aHUS was described.38
Dose modification or eculizumab 
discontinuation
In the prospective trials,31 the six patients in trial 1 (“progres-
sive TMA”) and two patients in trial 2 (“longstanding TMA”) 
discontinued treatment with eculizumab, with no overt TMA 
reported up to 8 weeks after withdrawal.
In a separate cohort, Cugno et al114 used a complement 
activity assay (Wieslab) to measure alternative lectin–mannose 
and classical pathways in patients receiving eculizumab. 
Complement activity was completely suppressed at 1 week, 
2 weeks, and 3 weeks after the last eculizumab infusion but 
only partially suppressed after 4 weeks.
The largest case series of eculizumab discontinuation 
was provided by Ardissino et al115 and Carr and Cataland,116 
who published the outcome of eculizumab discontinuation in 
ten patients aiming at minimizing adverse reactions, includ-
ing meningitis risk and infusion discomfort, and reducing 
costs. Patient monitoring was home-based and consisted of 
urine dipstick testing for blood. During the 95 months of 
observation, one-third of the patients experienced a relapse 
(median within 1.5 months), but recovery after eculizumab 
was restarted. More recently, Ardissino et al117 published the 
results of longer follow-up period after discontinuation, and 
a report of six additional cases. Patients had received eculi-
zumab for a median of 4.3 months (range, 0.5–14.4 months). 
Eight patients were able to discontinue dialysis therapy, 
whereas the other eight had never been dialyzed. During a 
cumulative time off treatment of 243 months, five patients 
experienced relapse, identified by means of regular home 
urine dipstick testing, within 6 months of the last eculizumab 
dose (an average of one relapse per 49 months off therapy). In 
these patients, eculizumab therapy was restarted, followed by 
rapid improvement in serum creatinine levels and proteinuria 
to or below baseline values, and maintained every 3 weeks or 
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4 weeks based on global complement activity. Eleven patients 
remained in remission with no signs of acute disease.
The authors concluded that, in aHUS, it is possible and 
relatively safe to discontinue eculizumab therapy. They 
discourage discontinuation of eculizumab therapy in kidney 
transplant recipients with CFH mutations and patients with 
glomerular filtration rates below 20 mL/min/1.73 m2. In 
patients with anti-CFH antibodies, one should consider dis-
continuation of eculizumab therapy when the antibody titer 
is ,2.5 times ULN. Regular home urine dipstick monitoring 
is suggested for early identification of relapses, especially 
during acute illnesses and when patients feel unwell.
After the publication of this case series, Wetzels and van de 
Kar118 added data for eculizumab treatment discontinuation in 
patients with aHUS and a CFH mutation. In their report, the 
authors treated four such patients who were plasma-resistant 
or -dependent and received eculizumab in accordance with 
FDA-proposed schedules. By local protocol, treatment is dis-
continued after 4–6 months if disease activity has disappeared 
and kidney function has improved and stabilized for at least 
4–6 weeks. Eculizumab treatment was withdrawn in three of 
four patients, two of whom had no signs of disease activity as of 
their respective 11-month and 17-month follow-ups. Recurrent 
disease developed in one patient 3 months after eculizumab 
therapy discontinuation. When they compared these patients 
with those of Ardissino et al,117 they noted a difference in the 
location of the CFH mutations, suggesting that patients with a 
mutation in exons 19 or 20 may be more prone to recurrence.
There are reports of temporary use of eculizumab in 
drug-induced TMA. Faguer et al3 published on use of seven 
doses of eculizumab starting 30 days after mitomycin 
C-induced TMA with reversal and no relapse after 1 year 
of follow-up. At the same time, Gilbert et al2 published the 
case of a 2-year-old patient with TMA after cisplatin therapy 
for neuroblastoma for whom eculizumab was administered 
for 2 months—there was a relapse 2 months after stopping 
eculizumab, and the patient was found to have a pathogenic 
variant in CD46, resuming treatment with complement 
blockade with good outcome.
Case reports of discontinuation of eculizumab in patients 
with aHUS are summarized in Table 5.
Failure of response to eculizumab: 
possible underlying mechanisms
When patients fail to respond to eculizumab or have frequent 
episodes of overt hemolysis during treatment, it is important 
to address the underlying mechanism of resistance, especially 
associated conditions that enhance complement responses 
such as infections, drugs, chemotherapy, or surgery, among 
others.
Mechanisms of TMA not primarily related to complement 
defects have been described in poor responders to eculi-
zumab, such as methylmalonic aciduria and homocystinuria 
type C protein mutations with elevated homocysteine levels, 
which may occur even in adult-onset aHUS119 and in a case 
of monoclonal proteinuria.120
Although the underlying mechanism is still unknown, 
Schalk et al74 described a 3-year-old boy with aHUS due to a 
novel heterozygous truncating complement Factor H mutation 
in combination with other changes known to be associated 
with an increased risk for aHUS. Despite eculizumab treat-
ment and maximal suppression of the classical and alternative 
complement pathways, C3d and sC5b-9 remained consistently 
elevated and were confirmed by augmented serum-induced 
endothelial C5b-9 deposits. The patient showed repeated 
relapses, reflected in ongoing activation in vivo, despite the 
full inhibition of global AP activity (CH50, APH50) in vitro. 
The authors state that no laboratory-confirmed parameter 
definitively reflects the situation on endothelial cells, where 
microangiopathy is localized. Nevertheless, the initial diagno-
sis of nonresponse was made on the basis of persistently low 
C3 (which is commonly seen after treatment), as well as other 
parameters not acceptably reliable. Insufficient data are given 
to judge whether relapses were indeed relapses or not.
In a cohort of 345 Japanese patients with PNH who 
received eculizumab, eleven patients had a poor response. 
All of them had a single missense C5 heterozygous mutation, 
whose prevalence among the patients with PNH (3.2%) was 
similar to that among healthy Japanese persons (3.5%), and 
which was also identified in the Han Chinese population. 
A patient of Asian ancestry in Argentina who had a poor 
response had a very similar mutation. Both C5 (with and 
without the mutation) caused hemolysis in vitro, but only C5 
without the mutation was able to bind to and have its hydro-
lysis prevented by eculizumab.121 To date, similar mutations 
in C5 have not been described in patients with aHUS.
Summary and conclusion
The molecular understanding of the mechanism of TMA 
related to aHUS has led to the novel therapeutic application 
of a C5 inhibitor, eculizumab. Controlled clinical trials, fol-
lowing upon dozens of case reports and a few case series, 
confirm that aHUS may be controlled in the overwhelming 
majority of patients and likely at a higher frequency than 
with PE alone by historical database comparisons. Recent 
consensus guidelines and our extensive review support that 
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the drug has become the treatment of choice for patients of 
all ages with aHUS.
Despite the impressive clinical outcomes using eculi-
zumab in a variety of circumstances in patients with aHUS 
that were summarized in our review, there remain absent 
biomarkers of disease diagnosis, ongoing clinical activity, 
or response to the drug. As with all pharmacologic agents, 
risks and side effects may occur; however, in aHUS, these 
are largely outweighed by efficacy.
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